The landscape of therapeutics for Niemann-Pick Disease Type C (NPC) is a rapidly changing one, with notable strides being made in investigation. Several promising therapeutic strategies are currently progressing pre-clinical evaluation, offering hope for patients living with this infrequent and deteriorating neurodegenerative disorder. A combinati